OCGN vs. LXEO, ADPT, ITOS, VYGR, REPL, HUMA, JSPR, CRBU, AURA, and TRML
Should you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Lexeo Therapeutics (LXEO), Adaptive Biotechnologies (ADPT), iTeos Therapeutics (ITOS), Voyager Therapeutics (VYGR), Replimune Group (REPL), Humacyte (HUMA), Jasper Therapeutics (JSPR), Caribou Biosciences (CRBU), Aura Biosciences (AURA), and Tourmaline Bio (TRML). These companies are all part of the "biological products, except diagnostic" industry.
Ocugen (NASDAQ:OCGN) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability.
10.3% of Ocugen shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 3.5% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ocugen received 94 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 68.49% of users gave Ocugen an outperform vote.
In the previous week, Ocugen had 15 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 17 mentions for Ocugen and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.60 beat Ocugen's score of 0.15 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.
Ocugen presently has a consensus target price of $4.67, indicating a potential upside of 266.53%. Lexeo Therapeutics has a consensus target price of $20.80, indicating a potential upside of 63.91%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than Lexeo Therapeutics.
Lexeo Therapeutics' return on equity of 0.00% beat Ocugen's return on equity.
Ocugen has higher revenue and earnings than Lexeo Therapeutics.
Summary
Lexeo Therapeutics beats Ocugen on 7 of the 13 factors compared between the two stocks.
Get Ocugen News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
